Innovation in action: achieving optimal outcomes in mitral regurgitation

Sponsored by Edwards Lifesciences

Facilitators: R. Smith, M. Urena

Discussants: M. Akodad, X. Freixa, M. I. Koerber, F. De Marco, T. Geisler

Summary

A growing mitral valve portfolio is reshaping how mitral regurgitation is treated, offering tailored solutions across a broader range of patient anatomies and clinical scenarios.

This EuroPCR 2026 session focuses on innovations in transcatheter mitral therapies, highlighting how mitral transcatheter edge-to-edge repair (TEER) with the PASCAL Precision system supports safe and predictable leaflet grasping, while expanding procedural confidence through refined device features and supporting evidence.

It also explores the role of transcatheter mitral valve replacement (TMVR) with the SAPIEN M3 system as an emerging option for patients who are not suitable for surgery or TEER, broadening therapeutic possibilities for complex mitral regurgitation cases.

Through evidence, simulation and case-based insights, the session illustrates how a portfolio-based approach can help optimise safety, expand indications and improve outcomes in mitral valve intervention.

Learning Objectives

To understand the benefit of a mitral portfolio to treat a wide range of mitral regurgitation patients
To discuss the key PASCAL Precison system features that facilitate a safe mitral TEER procedure, in evidence, simulation, and case-based discussion
To explore how TMVR with the SAPIEN M3 system can expand treatment options for mitral regurgitation patients with no other solution unsuitable for surgery or TEER in an evidence, simulation, and case-based discussion

Speaker

R. Smith

Welcome and session objectives